Literature DB >> 26522870

Prescription stimulant use is associated with earlier onset of psychosis.

Lauren V Moran1, Grace A Masters2, Samira Pingali2, Bruce M Cohen2, Elizabeth Liebson2, R P Rajarethinam2, Dost Ongur2.   

Abstract

A childhood history of attention deficit hyperactivity disorder (ADHD) is common in psychotic disorders, yet prescription stimulants may interact adversely with the physiology of these disorders. Specifically, exposure to stimulants leads to long-term increases in dopamine release. We therefore hypothesized that individuals with psychotic disorders previously exposed to prescription stimulants will have an earlier onset of psychosis. Age of onset of psychosis (AOP) was compared in individuals with and without prior exposure to prescription stimulants while controlling for potential confounding factors. In a sample of 205 patients recruited from an inpatient psychiatric unit, 40% (n = 82) reported use of stimulants prior to the onset of psychosis. Most participants were prescribed stimulants during childhood or adolescence for a diagnosis of ADHD. AOP was significantly earlier in those exposed to stimulants (20.5 vs. 24.6 years stimulants vs. no stimulants, p < 0.001). After controlling for gender, IQ, educational attainment, lifetime history of a cannabis use disorder or other drugs of abuse, and family history of a first-degree relative with psychosis, the association between stimulant exposure and earlier AOP remained significant. There was a significant gender × stimulant interaction with a greater reduction in AOP for females, whereas the smaller effect of stimulant use on AOP in males did not reach statistical significance. In conclusion, individuals with psychotic disorders exposed to prescription stimulants had an earlier onset of psychosis, and this relationship did not appear to be mediated by IQ or cannabis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amphetamine; Attention deficit hyperactivity disorder; Methylphenidate; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26522870      PMCID: PMC4630672          DOI: 10.1016/j.jpsychires.2015.09.012

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  60 in total

1.  Stimulant medication use in children: a 12-year perspective.

Authors:  Samuel H Zuvekas; Benedetto Vitiello
Journal:  Am J Psychiatry       Date:  2012-02       Impact factor: 18.112

2.  Illicit use of prescribed stimulant medication among college students.

Authors:  Kristina M Hall; Melissa M Irwin; Krista A Bowman; William Frankenberger; David C Jewett
Journal:  J Am Coll Health       Date:  2005 Jan-Feb

3.  Methamphetamine use and schizophrenia: a population-based cohort study in California.

Authors:  Russell C Callaghan; James K Cunningham; Peter Allebeck; Tamara Arenovich; Gautam Sajeev; Gary Remington; Isabelle Boileau; Stephen J Kish
Journal:  Am J Psychiatry       Date:  2012-04       Impact factor: 18.112

4.  The global market for ADHD medications.

Authors:  Richard M Scheffler; Stephen P Hinshaw; Sepideh Modrek; Peter Levine
Journal:  Health Aff (Millwood)       Date:  2007 Mar-Apr       Impact factor: 6.301

Review 5.  A systematic review of prospective studies on attention problems and academic achievement.

Authors:  Tinca J C Polderman; D I Boomsma; M Bartels; F C Verhulst; A C Huizink
Journal:  Acta Psychiatr Scand       Date:  2010-06-28       Impact factor: 6.392

Review 6.  Cannabis use and earlier onset of psychosis: a systematic meta-analysis.

Authors:  Matthew Large; Swapnil Sharma; Michael T Compton; Tim Slade; Olav Nielssen
Journal:  Arch Gen Psychiatry       Date:  2011-02-07

7.  Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients.

Authors:  J Rabinowitz; E J Bromet; J Lavelle; G Carlson; B Kovasznay; J E Schwartz
Journal:  Psychol Med       Date:  1998-11       Impact factor: 7.723

8.  Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.

Authors:  H Y Meltzer; J Rabinowitz; M A Lee; P A Cola; R Ranjan; R L Findling; P A Thompson
Journal:  Am J Psychiatry       Date:  1997-04       Impact factor: 18.112

9.  Risk of Schizophrenia Increases After All Child and Adolescent Psychiatric Disorders: A Nationwide Study.

Authors:  Cecilie Frejstrup Maibing; Carsten Bøcker Pedersen; Michael Eriksen Benros; Preben Bo Mortensen; Søren Dalsgaard; Merete Nordentoft
Journal:  Schizophr Bull       Date:  2014-09-05       Impact factor: 9.306

10.  The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective.

Authors:  Jan Zeidler; Lara Slawik; Jochen Fleischmann; Wolfgang Greiner
Journal:  Health Econ Rev       Date:  2012-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.